You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Dr Reddy's yet to apply for clinical trials of Sputnik V Covid-19 vaccine

Sources further added that there were no plans for any emergency-use authorisation of the Sputnik V without relevant and convincing local data

Topics
Dr Reddy's Laboratories | Coronavirus Vaccine

Sohini Das  |  Mumbai 

Covid-19 coronavirus
Russia has started production of the vaccine at two facilities owned by the RDIF

No matter how keen the Russian Direct Investment Fund (RDIF) is on bringing its Sputnik V to the Indian soil, the sovereign wealth fund’s distribution partner in India — Dr Reddy’s Laboratories (DRL) — is yet to file a formal application to start Phase 3 clinical trials (part of a multi-centre bridge trial of Sputnik V over 1,000 volunteers) here, said sources at the Central Drugs and Standards Control Organisation.

Sources further added that there were no plans for any emergency-use authorisation of the Sputnik V without relevant and convincing local data.

An email sent to DRL remained unanswered till the time of going to press.

Speaking at a webinar, Tagir Sitdekov, first deputy chief executive officer of RDIF, said they planned to start clinical trials here soon and that there have been no adverse side-effects so far. Five-thousand volunteers have received the jab.

Russia has started production of the vaccine at two facilities owned by the RDIF. The Gamaleya Research Institute of Epidemiology and Microbiology, too, has started production.

Sitdekov said RDIF is already in talks with Indian players for contract manufacturing the Sputnik V. No deal has been signed yet. Russia is also scouting for partners in China, Korea, and Brazil, apart from India.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, September 30 2020. 21:13 IST
RECOMMENDED FOR YOU